The role and mechanism of bone marrow-derived cells in pulmonary hypertension

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500102095

Enrollment

Unknown

Registered

2025-05-08

Start date

2025-06-01

Completion date

Unknown

Last updated

2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary hypertension

Interventions

PAH:None

Control:None

Eligibility

Sex/Gender

All

Age

10 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Patients with pulmonary hypertension (15) and volunteers with normal pulmonary hypertension (15) (2) Aged 10-60 years old; (3) Subject signs written informed consent

Exclusion criteria

Exclusion criteria: (1) Malignant tumor; (2) suffering from infectious diseases; (3) Suffering from other cardiovascular diseases (4) Reject the subjects.

Design outcomes

Primary

Measure	Time frame
Tricuspid regurgitation velocity;Mean pulmonary arterial pressure;Bone marrow cell type;Bone marrow cell single-cell transcriptome;	—

Secondary

Measure	Time frame
BMRP2;BMP9;	—

Countries

China

Contacts

Public ContactJie Yang

Second Hospital of the Army Medical University

yangjie0818@hotmail.com+86 186 2333 0911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026